Dexrazoxane functions by chelating iron, a process that prevents the formation of free radicals that can cause cardiac injury. Anthracyclines, such as doxorubicin, are known to generate free radicals, which are responsible for heart damage. By binding to iron, dexrazoxane reduces the oxidative stress on cardiac cells, thereby reducing the risk of cardiotoxicity.
